Arrowhead Pharmaceuticals (ARWR) Institutional Ownership
13F filers reported holding 9.1% of Arrowhead Pharmaceuticals (ARWR) shares as of Sep 30, 2026, across 200 filers.
- Held by 13F filers
- 9.1%
- Sep 30, 2026
- 13F filers
- 200
- quarter ended Sep 30, 2026
- 13F value
- $852.8M
- 12.9M shares
- Quarter's fund flow
- Mild distribution
- 24 new · 26 closed
Is the smart money (institutions and insiders) accumulating or distributing? One lagging input, not a buy signal.
| Date | Name | Role | Type | Shares | Price** | SEC filing |
|---|---|---|---|---|---|---|
| Aug 18, 2026 | PERRY MICHAEL S | director | Disposed · Open-market sale | 11,600 | $87.30 | ↗ |
| Aug 18, 2026 | OLUKOTUN ADEOYE Y | director | Disposed · Open-market sale | 2,000 | $86.96 | ↗ |
| Jun 15, 2026 | Cohen Matthew Gregory | director | Acquired · Grant / award | 11,882 | — | ↗ |
| May 12, 2026 | Lu Hongbo | director | Disposed · Open-market sale | 2,970 | $76.88 | ↗ |
| Apr 23, 2026 | Hamilton James C | Chief Medical Officer | Disposed · Open-market sale | 10,000 | $75.00 | ↗ |
| Apr 22, 2026 | Apel Daniel Joseph | Chief Financial Officer | Disposed · Open-market sale | 3,208 | $70.11 | ↗ |
| Apr 22, 2026 | Apel Daniel Joseph | Chief Financial Officer | Disposed · Open-market sale | 1,157 | $70.45 | ↗ |
| Apr 22, 2026 | Apel Daniel Joseph | Chief Financial Officer | Disposed · Open-market sale | 8,730 | $71.92 | ↗ |
| Mar 5, 2026 | Hamilton James C | Chief Medical Officer | Disposed · Open-market sale | 10,000 | $64.19 | ↗ |
| Jan 6, 2026 | Apel Daniel Joseph | Chief Financial Officer | Acquired · Grant / award | 75,000 | — | ↗ |
| Jan 6, 2026 | Hamilton James C | Chief Medical Officer | Acquired · Grant / award | 75,000 | — | ↗ |
| Jan 6, 2026 | O'Brien Patrick | COO | Disposed · Gift | 540 | — | ↗ |
| Jan 6, 2026 | O'Brien Patrick | COO | Disposed · Gift | 540 | — | ↗ |
| Jan 6, 2026 | O'Brien Patrick | COO | Disposed · Gift | 540 | — | ↗ |
| Jan 6, 2026 | O'Brien Patrick | COO | Disposed · Gift | 440 | — | ↗ |
| Jan 6, 2026 | O'Brien Patrick | COO | Disposed · Gift | 440 | — | ↗ |
| Jan 6, 2026 | O'Brien Patrick | COO | Acquired · Grant / award | 75,000 | — | ↗ |
| Jan 5, 2026 | Hamilton James C | Chief Medical Officer | Disposed · Open-market sale | 4,625 | $61.24 | ↗ |
| Jan 5, 2026 | Hamilton James C | Chief Medical Officer | Disposed · Open-market sale | 6,090 | $62.28 | ↗ |
| Jan 5, 2026 | Hamilton James C | Chief Medical Officer | Disposed · Open-market sale | 14,792 | $63.01 | ↗ |
* Holdings as reported for Sep 30, 2026, 49 days old; funds file up to 45 days after each quarter-end, so the newest complete quarter runs 45 to 135 days behind.
** A price of “—” marks an option exercise, RSU vest or a filing without a usable per-share price, not a $0 trade.
Common questions
How much of Arrowhead Pharmaceuticals do institutions hold?
13F filers reported holding 9.1% of Arrowhead Pharmaceuticals' shares as of Sep 30, 2026, across 200 filers.
How many 13F filers hold Arrowhead Pharmaceuticals?
Arrowhead Pharmaceuticals was held by 200 13F filers as of Sep 30, 2026.
Not investment advice.

